Loading
Life sciences · Journal article
Materials Today Chemistry · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Herein, we developed a water-stable ZnGlu bio-metal-organic framework (Bio-MOF) composed of biocompatible zinc ions and l -glutamic acid as a green nanocarrier for the targeted delivery of quercetin (Qu), a hydrophobic natural anticancer agent. Successful loading of quercetin into ZnGlu framework was achieved by an in situ loading method with high drug loading capacity (57.8%) and loading efficiency (92.4%). To improve tumor targeting and biocompatibility, the carrier surface was modified with folic acid-conjugated bovine serum albumin (FA-BSA). Structural and morphological analyses confirmed the successful preparation of the Qu@ZnGlu@FA-BSA nanocarrier and the preservation of the framework integrity after drug loading and surface modification. The system displayed prolonged and pH-responsive drug release with enhanced quercetin release under acidic conditions mimicking the tumor microenvironment. The fluorescence microscopy revealed enhanced cellular uptake of Qu@ZnGlu@FA-BSA in MDA-MB-231 breast cancer cells, which is attributed to folate receptor-mediated endocytosis. Moreover, the MTT and Annexin V-FITC/PI assays showed increased anticancer activity and apoptosis induction as compared to free quercetin and non-functionalized Qu@ZnGlu, resulting in a low IC50 value (24.6 μg/mL) against MDA-MB-231 cells. The results of this study indicate that FA-BSA-modified ZnGlu Bio-MOFs represent a promising platform for targeted and pH-responsive quercetin delivery in cancer therapy.